Analysis of Differential Expression of Synaptic Vesicle Protein 2A in the Adult Rat Brain


Por: Mendoza-Torreblanca J.G., García-Cruz M.E., Sánchez-Cruz I., Gomez-Gonzalez B., Juárez-Méndez S., Gómez-Lira G.

Publicada: 1 ene 2019
Categoría: Neuroscience (miscellaneous)

Resumen:
Synaptic vesicle protein 2A (SV2A), which plays an important role in the pathophysiology of epilepsy, is a unique vesicular protein recognized as a pharmacological target of anticonvulsant drugs. Furthermore, SV2A is a potential synaptic density marker, as it is ubiquitously expressed throughout the brain in all nerve terminals independently of their neurotransmitter content. Due to the growing interest in this protein, we thoroughly analyzed SV2A levels, expression patterns and colocalization in both excitatory and inhibitory synapses among different brain structures in healthy rats. In addition, we discuss the main semiquantitative methodologies used to study SV2A because these techniques might represent powerful tools for evaluating synaptic changes associated with brain disorders. Our results showed that the SV2A expression levels differed among the analyzed structures, and a positive correlation between the SV2A mRNA copy number and protein level was observed by Western blot. In addition, immunohistochemistry demonstrated slight but consistent asymmetrical SV2A levels in different laminated structures, and SV2A expression was increased by up to 40% in some specific layers compared to that in others. Finally, triple immunofluorescence revealed strong SV2A colocalization with GABAergic terminals, mainly around the principal cells, suggesting that SV2A primarily participates in this inhibitory system in different rat brain structures. Although the SV2A protein is considered a good candidate marker of synaptic density, our data show that changes in its expression in pathological processes must be viewed as not only increased or decreased synapse numbers but also in light of the type of neurotransmission being affected. © 2019 IBRO

Filiaciones:
Mendoza-Torreblanca J.G.:
 Neurosciences Laboratory, Instituto Nacional de Pediatría, Insurgentes Sur 3700 Letra C, Insurgentes Cuicuilco, Ciudad de México, 04530, Mexico

García-Cruz M.E.:
 Neurosciences Laboratory, Instituto Nacional de Pediatría, Insurgentes Sur 3700 Letra C, Insurgentes Cuicuilco, Ciudad de México, 04530, Mexico

Sánchez-Cruz I.:
 Experimental Oncology Laboratory, Instituto Nacional de Pediatría, Ciudad de México, Mexico

Gomez-Gonzalez B.:
 Area of Neurosciences, Department of Biology of Reproduction, Universidad Autónoma Metropolitana, Unidad Iztapalapa, Av. San Rafael Atlixco 186, Vicentina, 09340 Ciudad de México, Mexico

Juárez-Méndez S.:
 Experimental Oncology Laboratory, Instituto Nacional de Pediatría, Ciudad de México, Mexico

Gómez-Lira G.:
 Department of Pharmacobiology, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, Calzada de los Tenorios 235, Col. Granjas Coapa, C.P. 14330 Ciudad de México, Mexico
ISSN: 03064522
Editorial
PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 419 Número:
Páginas: 108-120
WOS Id: 000498390200011
ID de PubMed: 31520710